NantKwest to Host 2nd Annual Investor/Analyst Day Highlighting Industry Leading R&D and Clinical Programs
19 12월 2016 - 7:00PM
Business Wire
NantKwest (Nasdaq:NK), a pioneering, next generation,
clinical-stage immunotherapy company focused on harnessing the
unique power of the human immune system using natural killer (NK)
cells to treat cancer, infectious diseases and inflammatory
diseases today announced that the company will be hosting an
Investor/Analyst Day on January 8th in San Francisco.
NantKwest will be sharing with analysts and investors a review
of the company’s activities in 2016 and provide an overview for
2017.
At this event, senior management of NantKwest will provide a
review of its ongoing R&D program, as well as provide an
in-depth clinical trial roadmap for the aNK, haNK and taNK clinical
programs for 2017.
In addition to senior management presentations, the event will
feature presentations by key opinion leaders in the immunotherapy
field.
A webcast of the event will begin at 5:00 PM PT on Sunday,
January 8, 2017 and is expected to conclude at 7:30 PT. A link to
the live webcast can be accessed by visiting the Investors page of
the company's website. In addition, a replay of the event will be
posted on the website after the event and will be available for 30
days following the event.
About NantKwest
NantKwest (Nasdaq:NK) is a pioneering, next generation,
clinical-stage immunotherapy company focused on harnessing the
unique power of our immune system using natural killer (NK) cells
to treat cancer, infectious diseases and inflammatory diseases. NK
cells are the body’s first line of defense due to the innate
ability of NK cells to rapidly identify and destroy cells under
stress, such as cancer or virally-infected cells.
NantKwest’s unique NK cell-based platform, with the capacity to
grow active killer cells as a biological cancer therapy, has been
designed to induce cell death against cancer or infected cells by
three different modes of action: (1) Direct killing using activated
NK cells (aNK) that release toxic granules directly into the cell
through cell to cell contact, (2) Antibody-mediated killing using
haNKs, which are NK cells engineered to incorporate a high affinity
receptor that binds to an administered antibody, enhancing the
cancer cell killing effect of that antibody, and (3) Targeted
activated killing using taNKs, which are NK cells engineered to
incorporate chimeric antigen receptors (CARs) to target
tumor-specific antigens found on the surface of cancer cells.
Our aNK, haNK and taNK platform addresses certain limitations of
T cell therapies including the reduction of risk of serious
"cytokine storms" reported after T cell therapy. As an
“off-the-shelf” therapy, NantKwest's NK cells do not rely on a
patient’s own often compromised immune system. In Phase 1 clinical
trials in patients with late stage cancer, NantKwest's NK cells
have been successfully administered as an outpatient infusion
therapy without any reported severe side effects, even at doses of
10 billion cells.
By leveraging an integrated and extensive genomics and
transcriptomics discovery and development engine, together with a
pipeline of multiple, clinical-stage, immuno-oncology programs that
include a Phase 2 trial for a rare form of melanoma and the planned
initiation of a clinical trial of NK cells targeted to breast
cancer, we believe NantKwest is uniquely positioned to be the
premier immunotherapy company and transform medicine by delivering
living drugs in a bag and bringing novel NK cell-based therapies to
routine clinical care. For more information, please visit
www.nantkwest.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161219005422/en/
NantKwestMedia Contact:Jen Hodson, Public Relations
DirectorCell, 562-397-3639jhodson@nantworks.comorInvestor
Contact:David Pyrce, SVP, Innovation and Chief Commercial
OfficerCell, 951-551-0949david.pyrce@nantkwest.com
NantKwest (NASDAQ:NK)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
NantKwest (NASDAQ:NK)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024